glp 1 mechanism of action Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Current Insights, Advantages and Challenges

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with adverse outcomes such as cirrhosis, malignancy, transplantation, and mortality

In this narrative review we introduce the preclinical data related to this receptor pathway and pancreatic ductal adenocarcinoma

Stanford Medicine psychiatrist Anna Lembke unpacks the potential of FDA-approved weight-reducing GLP-1 drugs like Ozempic as tools in treating addiction.

they may also have direct effects in the brain (animal studies show neuroprotection and reduced amyloid/tau pathology)

This study demonstrated that the long-acting GLP-1R agonist, NLY01, has different health benefits in two different mouse models of MS